<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Shigella infection: Treatment and prevention in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Shigella infection: Treatment and prevention in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Shigella infection: Treatment and prevention in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rabia Agha, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marcia B Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Shigella
         </em>
         species are a common cause of bacterial diarrhea worldwide.
        </p>
        <p>
         The treatment and prevention
         <em>
          Shigella
         </em>
         infection in adults will be reviewed here. The epidemiology, microbiology, clinical manifestations, and diagnosis of
         <em>
          Shigella
         </em>
         , as well as the management of
         <em>
          Shigella
         </em>
         infection in children, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6003.html" rel="external">
          "Shigella infection: Treatment and prevention in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NATURAL HISTORY OF INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with
         <em>
          Shigella
         </em>
         is generally self-limited; the average duration of symptoms associated with untreated
         <em>
          Shigella
         </em>
         gastroenteritis is seven days [
         <a href="#rid1">
          1
         </a>
         ]. In the absence of antibiotic treatment, patients with
         <em>
          Shigella
         </em>
         gastroenteritis may shed the organism for up to six weeks after the resolution of symptoms; risk factors for asymptomatic shedding are not known.
        </p>
        <p>
         Complications of
         <em>
          Shigella
         </em>
         gastroenteritis, including bacteremia and severe colonic disease resulting in obstruction or perforation, are rare in immunocompetent adults. However, individuals with underlying immunodeficiency (including human immunodeficiency virus [HIV] infection) or malnutrition are at increased risk for complications and worse outcomes associated with
         <em>
          Shigella
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1768650074">
         <span class="h1">
          MICROBIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H13815531">
         <span class="h2">
          Shigella species
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among Shigella species causing infection in the United States,
         <em>
          S. sonnei
         </em>
         is most common, particularly among children, and
         <em>
          S. flexneri
         </em>
         is the next most common. Disease caused by
         <em>
          S. sonnei
         </em>
         tends to be less severe than that caused by
         <em>
          S. flexneri
         </em>
         .
         <em>
          S. dysenteriae
         </em>
         occurs only in individuals with international exposure, and
         <em>
          S. boydii
         </em>
         is currently limited to the Indian subcontinent.
        </p>
        <p>
         Species of
         <em>
          Shigella
         </em>
         and epidemiologic burden of disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Microbiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Burden of disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Antibiotic resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Shigella
         </em>
         species have emerged with resistance to several antibiotics, including fluoroquinolones, cephalosporins and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. The major route for dissemination of resistance is via horizontal transfer of plasmids carrying antibiotic resistance genes [
         <a href="#rid3">
          3-6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Antibiotic-resistant
         <em>
          Shigella
         </em>
         infections have been observed more frequently among the following patient groups:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Men who have sex with men (MSM) [
         <a href="#rid7">
          7,8
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         People with HIV infection
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         People experiencing homelessness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with infection acquired in Asia or Africa (such as in the context of international travel or adoption)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Global epidemiology
         </strong>
         – Globally, antibiotic-resistant
         <em>
          Shigella
         </em>
         infections are the most common cause of moderate to severe diarrhea among children [
         <a href="#rid9">
          9-11
         </a>
         ]. Antimicrobial resistance was first reported in Asia, Africa, and South America in the 1990s. In Asia and Africa, 65 to 85 percent of isolates are resistant to nalidixic acid (a quinolone) and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and 20 to 30 percent are resistant to fluoroquinolones. Resistance to nalidixic acid has also been reported in England. Resistance to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         has been reported in Asia [
         <a href="#rid12">
          12,13
         </a>
         ] and Europe [
         <a href="#rid14">
          14
         </a>
         ]. A clone that has spread through parts of Vietnam displays resistance to third-generation cephalosporins and fluoroquinolones [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology within the United States
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extensively drug-resistant (XDR) strains
         </strong>
         – In 2023, the United States Centers for Disease Control and Prevention (CDC) issued a health advisory regarding an increase in XDR
         <em>
          Shigella
         </em>
         infections reported through national surveillance systems [
         <a href="#rid16">
          16
         </a>
         ]. CDC defines XDR
         <em>
          Shigella
         </em>
         bacteria as strains with resistance to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In 2022, about 5 percent of
         <em>
          Shigella
         </em>
         infections reported to CDC were caused by XDR strains, compared with 0 percent in 2015. Of these, approximately 80 percent occurred in males; of these, most who provided sexual history reported male-to-male sexual contact [
         <a href="#rid16">
          16
         </a>
         ]. Similar XDR
         <em>
          Shigella
         </em>
         isolates have been identified in England and France, largely among MSM as well as among males with recent travel to South Asia or Southeast Asia [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Routine resistance monitoring
         </strong>
         – In the United States, among the 3079
         <em>
          Shigella
         </em>
         isolates tested by the National Antimicrobial Resistance Monitoring System (NARMS) for enteric bacteria by whole genome sequencing during 2022, the following results were reported [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         – 10.9 percent resistant
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         – 54.3 percent decreased susceptibility
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         – 32.1 percent resistant
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          Ampicillin
         </a>
         – 67.8 percent resistant
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         – 63.3 percent resistant
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Nalidixic acid – 31.8 percent resistant
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In 2022, 89 percent of isolates tested by whole genome sequencing were resistant to three or more Clinical and Laboratory Standards Institute (CLSI) antimicrobial classes [
         <a href="#rid19">
          19
         </a>
         ], and 5 percent were extensively drug resistant (defined above) [
         <a href="#rid20">
          20
         </a>
         ]. There are substantial differences in resistance rates among states; the NARMS data may be used to understand regional resistance rates.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         <strong>
          susceptibility breakpoint
         </strong>
         – Due to an increasing proportion of
         <em>
          Shigella
         </em>
         isolates in the United States with ciprofloxacin minimum inhibitory concentration (MIC) &gt;0.12 mcg/mL, in 2018 the CLSI changed the breakpoints for ciprofloxacin to the following: susceptible, MIC ≤0.12 mcg/mL; intermediate, MIC 0.25 to 0.5 mcg/mL; and resistant ≥1 mcg/mL [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Directed therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H8687025">
         <span class="h2">
          Supportive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hydration is important to compensate for fluid loss from the gastrointestinal tract; oral rehydration is sufficient in most cases. Issues related to fluid repletion are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">
          "Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Fluid repletion'
         </a>
         .)
        </p>
        <p>
         We avoid antimotility agents in patients with clinical features suggestive of dysentery (fever, bloody or mucoid stools) because of concerns that antimotility agents can prolong disease in such infections or lead to more severe illness [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">
          "Oral rehydration therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">
          "Maintenance and replacement fluid therapy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Antibiotic treatment
         </span>
        </p>
        <p class="headingAnchor" id="H1111772046">
         <span class="h3">
          Indications
         </span>
        </p>
        <p class="headingAnchor" id="H2555733637">
         <span class="h4">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the evolving drug-resistance among
         <em>
          Shigella
         </em>
         isolates worldwide, the optimal approach to antibiotic treatment is uncertain. Here, we describe our approach and note how it differs slightly from guidance issued by the United States Centers for Disease Control and Prevention (CDC).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients
         </strong>
         – For patients with
         <em>
          Shigella
         </em>
         infection who are immunocompromised and/or have severe disease (characterized by bacteremia, intestinal or extraintestinal complications, or need for hospitalization), we recommend antibiotic therapy. For other symptomatic adults with
         <em>
          Shigella
         </em>
         infection, we suggest antibiotic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach differs from the guidance issued by the CDC. (See
         <a class="local">
          'Guidance from CDC'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Advantages of treatment
         </strong>
         – Antibiotic treatment may shorten the duration of fever and diarrhea by about two days [
         <a href="#rid22">
          22
         </a>
         ]. In addition, antibiotic treatment may shorten the duration of pathogen shedding in stool, which may confer public health benefit by reducing the risk of person-to-person spread; however, data to support this assertion are limited. The household secondary attack rate for
         <em>
          Shigella
         </em>
         infection is approximately 20 percent [
         <a href="#rid23">
          23
         </a>
         ]. Small, randomized trials in adults and children have demonstrated reduction in bacterial shedding with antibiotic treatment (two to five days versus up to four weeks with placebo) [
         <a href="#rid22">
          22,24-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low concern for hemolytic uremic syndrome (HUS)
         </strong>
         – Antibiotic treatment of
         <em>
          S. dysenteriae
         </em>
         infection has not been observed to increase the incidence of HUS [
         <a href="#rid28">
          28
         </a>
         ], in contrast to HUS associated with enterohemorrhagic
         <em>
          Escherichia coli
         </em>
         (EHEC) or Shiga toxin-producing
         <em>
          E. coli
         </em>
         (STEC). This may be because the mechanism that controls Shiga toxin production in
         <em>
          S. dysenteriae
         </em>
         is distinct from EHEC or STEC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are no longer symptomatic
         </strong>
         – We do not give antibiotics to patients with
         <em>
          Shigella
         </em>
         whose symptoms resolve prior to microbiologic diagnosis in the absence of antibiotic therapy, unless there are public health concerns (for example, the patient is a food handler and may shed
         <em>
          Shigella
         </em>
         organisms asymptomatically with risk for transmission to others). (See
         <a class="local">
          'Natural history of infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H740600110">
         <span class="h4">
          Guidance from CDC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach differs from the guidance issued by the United States the Centers for Disease Control and Prevention (CDC), which recommends reserving antibiotic treatment for individuals in the following categories, regardless of whether the illness occurs in the context of an outbreak [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are immunocompromised (including patients with HIV infection and CD4 count &lt;500 cells/microL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have severe disease characterized by bacteremia, intestinal or extraintestinal complications, or the need for hospitalization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are food handlers, childcare providers, residents of nursing homes, or otherwise in settings with the potential to spread the disease. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The CDC issued this guidance in the context of increasing fluoroquinolone MICs among
         <em>
          Shigella
         </em>
         isolates in the United States. (See
         <a class="local">
          'Antibiotic resistance'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1111772052">
         <span class="h3">
          Antibiotic selection
         </span>
        </p>
        <p class="headingAnchor" id="H2468465486">
         <span class="h4">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to empiric antibiotic therapy in the absence of stool culture data are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">
          "Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Empiric antibiotic therapy'
         </a>
         .)
        </p>
        <p>
         For treatment of patients with
         <em>
          Shigella
         </em>
         infection prior to availability of antimicrobial susceptibility data, antibiotic selection should be informed by the risk of drug resistance based on patient demographics and the local resistance prevalence [
         <a href="#rid19">
          19
         </a>
         ] (see
         <a class="local">
          'Antibiotic resistance'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who have no clear risk factors for drug resistance, treatment with a fluoroquinolone is reasonable; other acceptable agents are summarized in the table (
         <a class="graphic graphic_table graphicRef68382" href="/z/d/graphic/68382.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals at risk for drug-resistant infection (including men who have sex with men, international travelers, people with HIV infection and people experiencing homelessness), the clinical approach depends on the severity of illness:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are immunocompromised and/or have severe disease (characterized by bacteremia, intestinal or extraintestinal complications, or need for hospitalization), we suggest treatment with a carbapenem (such as
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         [1 g intravenous (IV) every 24 hours],
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         [500 mg IV every 6 hours], or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         [1 g IV every 8 hours]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with mild to moderate illness, initial empiric outpatient management with a fluoroquinolone is reasonable; in such cases, patients should be monitored carefully by telephone and the antibiotic regimen should be adjusted as needed once susceptibility results are available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2223623723">
         <span class="h4">
          Directed therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotic therapy should be tailored to antimicrobial susceptibility results when available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug-susceptible infection – In the absence of drug-resistant infection, treatment options include a fluoroquinolone,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , or a third-generation cephalosporin (
         <a class="drug drug_general" data-topicid="9216" href="/z/d/drug information/9216.html" rel="external">
          cefixime
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ).
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         are also options if susceptibility is documented. Doses and durations are included in the table (
         <a class="graphic graphic_table graphicRef68382" href="/z/d/graphic/68382.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Fluoroquinolones, macrolides, beta-lactams, and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         all have established efficacy for susceptible
         <em>
          Shigella
         </em>
         isolates. In a systematic review of 16 trials evaluating these different antibiotic regimens, there was no consistent evidence that one particular agent was superior to the others, although the overall quality of the data was low [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug-resistant infection – For management of infection due to drug-resistant
         <em>
          Shigella
         </em>
         , a carbapenem may be used; infectious disease consultation is advised.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility testing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fluoroquinolones
         </strong>
         –
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         susceptibility should be assessed carefully; fluoroquinolones should be avoided when the ciprofloxacin minimum inhibitory concentration (MIC) is &gt;0.12 mcg/mL [
         <a href="#rid4">
          4
         </a>
         ]. In one study including 15 patients with
         <em>
          S. sonnei
         </em>
         isolates with ciprofloxacin MICs of 0.12 mcg/mL, two patients experienced clinical and/or microbiological failure with ciprofloxacin treatment [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Antibiotic resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         – Many clinical laboratories do not routinely evaluate
         <em>
          Shigella
         </em>
         isolates for azithromycin susceptibility because there is no standardized testing. However, some laboratories can perform azithromycin susceptibility testing when requested; this should be done if available, especially for isolates from patients at risk for drug-resistant infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For
         <em>
          Shigella
         </em>
         species, MIC breakpoints for
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are ≤8 mcg/mL for susceptible, 16 mcg/mL for intermediate, and ≥32 mcg/mL for resistant. Disc diffusion breakpoints for azithromycin are ≥16 mm for susceptible, 11 to 15 mm for intermediate, and ≤10 mm for resistant [
         <a href="#rid29">
          29
         </a>
         ]. The zone of inhibition for azithromycin can be hazy and therefore difficult to interpret; when this is the case, we recommend requesting that MICs be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other agents
         </strong>
         – Addition of susceptibility testing for carbapenems and
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is useful for patients with known or suspected drug-resistant infection [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1194113061">
         <span class="h3">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of treatment for
         <em>
          Shigella
         </em>
         infection depends on the agent used and certain patient factors (
         <a class="graphic graphic_table graphicRef68382" href="/z/d/graphic/68382.html" rel="external">
          table 1
         </a>
         ). In general, fluoroquinolones and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are given for three days; beta-lactams are given for five days. However, for patients with infection due to
         <em>
          S. dysenteriae
         </em>
         type 1 or with HIV coinfection, five to seven days of therapy are warranted [
         <a href="#rid30">
          30-32
         </a>
         ]. In the setting of bacteremia, a 14-day course is reasonable.
        </p>
        <p class="headingAnchor" id="H4159318759">
         <span class="h2">
          Follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical improvement (eg, less frequent stools, less blood in the stools, lower fever, improved appetite) is expected within one to two days if
         <em>
          Shigella
         </em>
         infection is treated with an antibiotic to which the isolate is susceptible [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         If symptoms persist or worsen despite three days of treatment, repeat stool culture and susceptibility testing should be performed to evaluate for drug resistance or an alternative diagnosis.
        </p>
        <p>
         If symptoms persist despite treatment with an antibiotic to which the isolate has demonstrated in vitro susceptibility, other potential causes should be considered; pending further evaluation, switching to another antibiotic is reasonable. (See
         <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">
          "Approach to the adult with acute diarrhea in resource-abundant settings", section on 'Persistent diarrhea'
         </a>
         .)
        </p>
        <p>
         There is no role for routine follow-up stool cultures.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          PREVENTION
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General guidance
         </strong>
         – Patients with
         <em>
          Shigella
         </em>
         infection should be counseled on the following practices to reduce the risk of transmission:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Stay home from school or from healthcare, food service, or childcare jobs while sick or in conjunction with guidance from local health authorities.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Wash hands often with soap and water for at least 20 seconds, including at key times such as after using the toilet, before and after changing diapers or cleaning up after someone who is sick, and before preparing or eating food.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Do not prepare food for others, if possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Stay out of recreational water; this includes swimming pools, hot tubs, water playgrounds, oceans, lakes, and rivers.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Follow preventive measures related to sexual activity (
         <a class="graphic graphic_table graphicRef141964" href="/z/d/graphic/141964.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Food handlers, healthcare workers, and childcare workers
         </strong>
         – Decisions regarding follow-up evaluation and timing of safe return to work should be made in conjunction with guidance from local public health authorities; shigellosis is a nationally notifiable disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uninfected individuals
         </strong>
         – For uninfected individuals, preventive measures include frequent handwashing with soap and water, particularly after using the restroom or changing a child's diaper [
         <a href="#rid35">
          35
         </a>
         ]. In childcare centers, separate staff should be assigned to food preparation and diapering.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276049489">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">
          "Society guideline links: Acute diarrhea in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8687084">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Natural history
         </strong>
         –
         <em>
          Shigella
         </em>
         infection is usually self-limited; the average duration of symptoms associated with untreated
         <em>
          Shigella
         </em>
         gastroenteritis is seven days. (See
         <a class="local">
          'Natural history of infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic resistance
         </strong>
         –
         <em>
          Shigella
         </em>
         species have emerged with resistance to several antibiotics. In 2023, the United States Centers for Disease Control and Prevention (CDC) issued a health advisory regarding an increase in extensively drug-resistant (XDR)
         <em>
          Shigella
         </em>
         infections, defined as strains with resistance to
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         . Risk groups for drug-resistant
         <em>
          Shigella
         </em>
         infection include men who have sex with men (MSM), people with HIV infection, people experiencing homelessness, and patients with infection acquired in Asia or Africa. (See
         <a class="local">
          'Antibiotic resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive therapy
         </strong>
         (See
         <a class="local">
          'Supportive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hydration is important to compensate for fluid loss from the gastrointestinal tract; oral rehydration is sufficient in most cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with clinical features suggestive of dysentery (fever, bloody or mucoid stools), we suggest avoiding antimotility agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such cases, antimotility agents may prolong disease or lead to more severe illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Whom to treat
         </strong>
         – For adults with
         <em>
          Shigella
         </em>
         infection who are immunocompromised and/or have severe disease (characterized by bacteremia, intestinal or extraintestinal complications, or need for hospitalization), we recommend antibiotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For other symptomatic adults with
         <em>
          Shigella
         </em>
         infection, we suggest antibiotic therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We do not give antibiotics to patients with
         <em>
          Shigella
         </em>
         whose symptoms resolve prior to microbiologic diagnosis in the absence of antibiotic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antibiotic treatment may shorten the duration of fever and diarrhea (by about two days) and may shorten the duration of pathogen shedding in stool, which may reduce the risk of person-to-person spread. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic selection
         </strong>
         – For empiric treatment of patients with
         <em>
          Shigella
         </em>
         infection prior to availability of antimicrobial susceptibility data, antibiotic selection should be informed by the risk of drug resistance (see
         <a class="local">
          'Empiric therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No risk for drug resistance
         </strong>
         – For patients who have no clear risk factors for drug resistance, we suggest empiric treatment with a fluoroquinolone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); other acceptable agents are summarized in the table (
         <a class="graphic graphic_table graphicRef68382" href="/z/d/graphic/68382.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients at risk for drug-resistant infection
         </strong>
         – For patients at risk for drug-resistant infection (including MSM, international travelers, people with HIV infection and people experiencing homelessness), the clinical approach depends on the severity of illness:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who are immunocompromised and/or have severe disease (characterized by bacteremia, intestinal or extraintestinal complications, or need for hospitalization), we suggest treatment with a carbapenem (such as
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with mild to moderate illness, we suggest initial outpatient management with a fluoroquinolone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); in such cases, patients should be monitored carefully by telephone and the antibiotic regimen should be adjusted as needed once susceptibility results are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antibiotic therapy should be tailored to antimicrobial susceptibility results when available. (See
         <a class="local">
          'Directed therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow up
         </strong>
         – Clinical improvement is expected within one to two days if
         <em>
          Shigella
         </em>
         infection is treated with an antibiotic to which the isolate is susceptible. If symptoms persist or worsen despite three days of treatment, repeat stool culture and susceptibility testing should be performed to evaluate for drug resistance or an alternative diagnosis. If symptoms persist despite treatment with an antibiotic to which the isolate has demonstrated in vitro susceptibility, other potential causes should be considered; pending further evaluation, switching to another antibiotic is reasonable. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         (see
         <a class="local">
          'Prevention'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients should be counseled on practices to reduce the risk of transmission, including frequent hand washing, avoidance of food preparation for others, and safe sexual practices (
         <a class="graphic graphic_table graphicRef141964" href="/z/d/graphic/141964.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For food handlers, healthcare workers, and childcare workers, decisions regarding follow-up testing and timing of safe return to work should be made in conjunction with guidance from local public health authorities.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Dupont HL. Shigella species (bacillary dysentery). In: Principles and Practice of Infectious Diseases, 6th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2655.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puzari M, Sharma M, Chetia P. Emergence of antibiotic resistant Shigella species: A matter of concern. J Infect Public Health 2018; 11:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gharpure R, Friedman CR, Fialkowski V, et al. Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018. Clin Infect Dis 2022; 74:455.
          </a>
         </li>
         <li class="breakAll">
          CDC Health Alert Network. CDC Recommendations for Diagnosing and Managing Shigella Strains with Possible Reduced Susceptibility to Ciprofloxacin. April 18, 2017. https://emergency.cdc.gov/han/han00401.asp (Accessed on April 24, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozyreva VK, Jospin G, Greninger AL, et al. Recent Outbreaks of Shigellosis in California Caused by Two Distinct Populations of Shigella sonnei with either Increased Virulence or Fluoroquinolone Resistance. mSphere 2016; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker KS, Dallman TJ, Field N, et al. Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species. Nat Commun 2018; 9:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiman KE, Karlsson M, Grass J, et al. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep 2014; 63:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen A, Eikmeier D, Talley P, et al. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. Lancet 2016; 388:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivett H. Increase in extensively drug resistant Shigella sonnei in Europe. Lancet Microbe 2022; 3:e481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason LCE, Greig DR, Cowley LA, et al. The evolution and international spread of extensively drug resistant Shigella sonnei. Nat Commun 2023; 14:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo CY, Su LH, Perera J, et al. Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect 2008; 41:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darton TC, Tuyen HT, The HC, et al. Azithromycin Resistance in Shigella spp. in Southeast Asia. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassing RJ, Melles DC, Goessens WH, Rijnders BJ. Case of Shigella flexneri infection with treatment failure due to azithromycin resistance in an HIV-positive patient. Infection 2014; 42:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holt KE, Thieu Nga TV, Thanh DP, et al. Tracking the establishment of local endemic populations of an emergent enteric pathogen. Proc Natl Acad Sci U S A 2013; 110:17522.
          </a>
         </li>
         <li class="breakAll">
          Increase in Extensively Drug-Resistant Shigellosis in the United States. Centers for Disease Control and Prevention (CDC). February 24, 2023. Available at: https://emergency.cdc.gov/han/2023/han00486.asp (Accessed on February 28, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefèvre S, Njamkepo E, Feldman S, et al. Rapid emergence of extensively drug-resistant Shigella sonnei in France. Nat Commun 2023; 14:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles H, Prochazka M, Thorley K, et al. Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study. Lancet Infect Dis 2022; 22:1503.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS). NARMS Now: Human data, Shigella, 2022. Available at: https://wwwn.cdc.gov/narmsnow (Accessed on March 27, 2023).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Health Advisory. Increase in Extensively Drug-Resistant Shigellosis in the United States. Available at: https://emergency.cdc.gov/han/2023/han00486.asp (Accessed on March 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson R, Feldman RA, Davis J, LaVenture M. Family illness associated with Shigella infection: the interrelationship of age of the index patient and the age of household members in acquisition of illness. J Infect Dis 1981; 143:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haltalin KC, Nelson JD, Ring R 3rd, et al. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J Pediatr 1967; 70:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother 1986; 29:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oldfield EC 3rd, Bourgeois AL, Omar AK, Pazzaglia GL. Empirical treatment of Shigella dysentery with trimethoprim: five-day course vs. single dose. Am J Trop Med Hyg 1987; 37:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haltalin KC, Kusmiesz HT, Hinton LV, Nelson JD. Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo. Am J Dis Child 1972; 124:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.
          </a>
         </li>
         <li class="breakAll">
          CLSI M100-ED32: 2022 performance standards for antimicrobial susceptibility testing, 32nd edition. http://em100.edaptivedocs.net/Login.aspx (Accessed on March 29, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992; 117:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassily S, Hyams KC, el-Masry NA, et al. Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am J Trop Med Hyg 1994; 51:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendrel D, Moreno JL, Nduwimana M, et al. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin Infect Dis 1997; 24:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islam MR, Alam AN, Hussain MS, Mahalanabis D. Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it. J Trop Med Hyg 1995; 98:121.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1 http://whqlibdoc.who.int/publications/2005/9241592330.pdf (Accessed on March 21, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis V, Cairncross S. Effect of washing hands with soap on diarrhoea risk in the community: a systematic review. Lancet Infect Dis 2003; 3:275.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2701 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Dupont HL. Shigella species (bacillary dysentery). In: Principles and Practice of Infectious Diseases, 6th Ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2655.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29066021" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Emergence of antibiotic resistant Shigella species: A matter of concern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33993224" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33993224" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28028547" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Recent Outbreaks of Shigellosis in California Caused by Two Distinct Populations of Shigella sonnei with either Increased Virulence or Fluoroquinolone Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29654279" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24522098" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26042652" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27673470" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35779565" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increase in extensively drug resistant Shigella sonnei in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37031199" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The evolution and international spread of extensively drug resistant Shigella sonnei.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18473096" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29378707" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Azithromycin Resistance in Shigella spp. in Southeast Asia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24488332" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Case of Shigella flexneri infection with treatment failure due to azithromycin resistance in an HIV-positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24082120" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Tracking the establishment of local endemic populations of an emergent enteric pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24082120" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Tracking the establishment of local endemic populations of an emergent enteric pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36709320" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Rapid emergence of extensively drug-resistant Shigella sonnei in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35809593" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35809593" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35809593" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4587313" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adverse effect of lomotil therapy in shigellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20687081" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antibiotic therapy for Shigella dysentery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7217710" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Family illness associated with Shigella infection: the interrelationship of age of the index patient and the age of household members in acquisition of illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5338090" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518625" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3688315" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Empirical treatment of Shigella dysentery with trimethoprim: five-day course vs. single dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4562790" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of acute diarrhea in outpatients. Double-blind study comparing ampicillin and placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16392080" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16392080" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1416574" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8074256" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Short-course norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8994771" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7714935" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7714935" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of antimicrobial (nalidixic acid) therapy in shigellosis and predictive values of outcome variables in patients susceptible or resistant to it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12726975" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of washing hands with soap on diarrhoea risk in the community: a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
